KeyBanc highlights supportive policy signals for cell and gene therapy stocks

KeyBanc Capital Markets sees positive momentum in the cell and gene therapy (CGT) sector, driven by supportive bipartisan policy, faster FDA approval pathways, and projected growth in approvals for 2025. The firm highlights BioLife Solutions (BLFS) with 22-25% growth visibility for 2025 and CryoPort (CYRX) demonstrating 33% commercial CGT revenue growth in Q2 2025 and an estimated 31.5% CAGR to 2030. Alpha Teknova (TKNO) also stands out, recently exceeding Q2 2025 revenue and EPS forecasts, despite a flat stock reaction, positioning these companies as key beneficiaries of the expanding CGT market.

Analysis

The cell and gene therapy (CGT) sector is exhibiting strong positive momentum, underscored by supportive bipartisan policy and efforts by regulatory bodies to create faster approval pathways. KeyBanc Capital Markets highlights this trend, noting a record seven FDA CGT approvals last year and an expectation for five to six in 2025. This backdrop directly benefits supply chain companies with significant CGT exposure. CryoPort (CYRX) stands out with a 33% increase in revenue from commercial cell and gene therapies in Q2 2025, a segment that now constitutes 20% of its total revenue, up from 10% a year prior, and is projected to grow at a 31.5% CAGR until 2030. BioLife Solutions (BLFS) demonstrates strong forward visibility, guiding for 22-25% growth in 2025, supported by a 28% growth in its Cell Processing Platform in Q2 2025. Concurrently, Alpha Teknova (TKNO) has posted solid fundamental results, beating Q2 2025 analyst expectations with revenue of $10.3 million and a net loss of $0.07 per share, better than the forecasted loss. Despite this, TKNO's stock remained flat, trading at $4.34, which is substantially below analyst price targets of $8 to $12, suggesting a potential disconnect between recent performance and market valuation.

Key Decisions for Investors

• Investors should consider the favorable regulatory environment and projected growth in FDA approvals as a secular tailwind for the CGT supply chain, warranting a review of portfolio exposure to companies like CYRX, BLFS, and TKNO.
• CryoPort's accelerating shift toward commercial therapies, evidenced by 33% Q2 revenue growth and a projected 31.5% CAGR, positions it as a primary growth vehicle within the sector that could see continued re-rating.
• The market's muted reaction to Alpha Teknova's Q2 2025 earnings and revenue beat, combined with its stock trading significantly below analyst targets, may present a valuation-based opportunity for investors confident in its fundamental trajectory.
• For BioLife Solutions, the key variable to monitor is the execution against its 2025 guidance of 22-25% growth; achieving this target is critical to sustaining the positive investment thesis.